Clinical Trials Logo

Chronic Schizophrenia clinical trials

View clinical trials related to Chronic Schizophrenia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06206798 Completed - Quality of Life Clinical Trials

Resourcefulness Group Intervention on Recovery and Quality of Life

Start date: June 6, 2022
Phase: N/A
Study type: Interventional

The purpose of this study was to test the effects of resourcefulness group intervention on facilitating recovery and improving the quality of life in patients with chronic schizophrenia.

NCT ID: NCT05809882 Completed - Clinical trials for Chronic Schizophrenia

Study of Experience of High-frequency Repetitive Transcranial

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Objective: To understand the personal experience of schizophrenia patients following repetitive transcranial magnetic stimulation (rTMS) and its connection with changes in mental symptoms, thereby enhancing the overall understanding of TMS. Method: The investigators selected eligible schizophrenia patients for fixed-parameter rTMS treatment. A self-experience checklist post-TMS treatment and positive and negative symptom scales (PANSS) were applied to evaluate the treatment.

NCT ID: NCT03275909 Completed - Clinical trials for Chronic Schizophrenia

Integrated Psychological Therapy for Chronic Schizophrenia

Start date: July 1, 2011
Phase: N/A
Study type: Interventional

Background: The chronic phase of schizophrenia (CS) that extremely affects the way people think, feel and act, underlines the need for effective interventions in patients affected by this disorder. The Integrated Psychological Therapy appears in clinical practice guidelines as the reference therapy in the treatment of this type of patients. In this paper authors propose to include in this program a new module focused on Emotional Management Therapy in order to reinforce its effectiveness. The aim of this study is to describe the design of a study protocol for a randomized controlled trial in which the objective is to assess the efficacy of this modified IPT program in patients with CS compared to treatment as usual (pharmacological treatment and social and leisure activities in a Day Care Center). Methods/design: This is a randomized study with pre and post-treatment assessment and with a 6- and 12-month follow-up. Patients are to be randomly assigned to one of two treatments: (1) a experimental group: integrated psychological therapy in conjunction with emotional management therapy (IPT+EMT), composed of 2-hour biweekly 60 group sessions for 32 weeks, in addition to the treatment as usual (TAU), or (2) a control group (treatment as usual). Participants in both groups will be evaluated at baseline (pre-treatment) and at post-treatment after 8 months. The primary outcome will be that patients in the experimental group will show a greater improvement over participants in the control group in reducing symptoms and increasing emotional abilities, as well as in improving their quality of life. The secondary outcome will be that these results will maintain at the 6- and 12-month follow-up in the experimental group.

NCT ID: NCT02624167 Completed - Clinical trials for Chronic Schizophrenia

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

Start date: December 2015
Phase: Phase 2
Study type: Interventional

A 4-week Phase IIa study to evaluate the safety and tolerability and efficacy of NW-3509A in patients with chronic schizophrenia that are not responding adequately to their current antipsychotic medication (aripiprazole or risperidone). NW-3509A is given as an oral dose range of 15 to 25 mg, BID in a 1:1 ratio.

NCT ID: NCT02421146 Completed - Clinical trials for Chronic Schizophrenia

The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study

Start date: April 2015
Phase: N/A
Study type: Interventional

The purpose of this project is to examine brain function before, during, and after the administration of tDCS (Transcranial Direct Current Stimulation). The brain can perform its job well or poorly depending on many things. The investigators will be using computer tasks and paper and pencil questionnaires to measure the relationship between brain performance and the administration of tDCS. In addition, the study team will be using functional magnetic resonance imaging (fMRI) and related imaging techniques to see how your brain works and compare it with the results we collected from the paper and pencil questionnaires. This study will enroll both schizophrenia patients as well as healthy volunteers without any major psychiatric disorder or physical illness.

NCT ID: NCT02298985 Completed - Clinical trials for Chronic Schizophrenia

Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients

Start date: January 2015
Phase: Phase 4
Study type: Interventional

Schizophrenia is still remained one of the disabling disorders despite progress in treatment of mental disturbances. Ten to thirty percents of patients have a little or no benefit from treatment with all kinds of antipsychotics using adequate dosages and duration. Treatment of these patients has remained a persistent public health problem since medication-resistant patients are often highly symptomatic. Curcumin is one of the main curcuminoids isolated from this perennial herb. It possesses a variety of pharmacological activities, including anti-inflammatory, antiproliferative, antioxidant, and neuroprotective effects and crosses the blood-brain barrier. The purpose of our suggested study is to examine the efficacy of curcumin as add-on the conventional antipsychotic psychopharmacotherapy in chronic schizophrenia patients.

NCT ID: NCT01891929 Completed - Clinical trials for Chronic Schizophrenia

Cognitive Remediation and Sheltered Employment in Schizophrenia

RemedRehab
Start date: July 2013
Phase: N/A
Study type: Interventional

This study, driven on schizophrenic patients, is aimed at : 1. Measuring the efficiency of the cognitive remediation program RECOS (COgnitive REmediation in Schizophrenia) on the capacity of the patients suffering from schizophrenia to improve the integration in sheltered employment (ESAT and EA). 2. Comparing the efficiency of the program of cognitive remediation RECOS (RECOS arm) to the one of an usual program of coverage/care (TAU arm = Treatment As Usual) on integration in sheltered employment of patients suffering from schizophrenia. 3. Realizing a comparative analysis, in both arms, of : 1. the number of working hours achieved in sheltered environment during the 6 months following the two programs (reported to the working time planned by the contract of employment) 2. the duration of such employments in sheltered areas. 4. Estimating the impact of RECOS on the neuropsychological variables, the symptomatology, the consciousness of the disorders(insight), the quality of life and the social autonomy before the treatment (month M0), at the end of the treatment (month M3), and 6 months later (month M9), and looking for a correlation between the improvement of these parameters and sheltered employment. 5. Estimating the impact of cognitive remediation on integration in sheltered employment.

NCT ID: NCT01761383 Completed - Clinical trials for Chronic Schizophrenia

Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia

Start date: June 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the use of Nintendo Wii will help improve negative symptoms of Schizophrenia and quality of life of patients with chronic Schizophrenia.

NCT ID: NCT01450514 Completed - Clinical trials for Schizoaffective Disorder

POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia

Start date: March 2012
Phase: Phase 2
Study type: Interventional

This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or paliperidone (PAL) on functional MRI tests and clinical outcome of chronic schizophrenic patients with residual, so-called 'positive' symptoms, as well as on cognition, motivation, subjective well-being of patients, negative symptoms, general psychopathological symptoms and safety/tolerability.

NCT ID: NCT00789698 Completed - Clinical trials for Chronic Schizophrenia

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

PEARL 3 Ext
Start date: December 2008
Phase: Phase 3
Study type: Interventional

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia.